Tirzepatide, AF screening, and an AHA preview, including VT ablation, LAAC at the time of AF ablation, BP targets, and GLP1 agonists in HF are the topics John Mandrola, MD, covers in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Tirzepatide
- SURMOUNT 1 – Three-year results https://www.nejm.org/doi/full/10.1056/NEJMoa2410819
II. AF Screening
- GUARD AF https://www.jacc.org/doi/10.1016/j.jacc.2024.08.019
- LOOP 10.1016/S0140-6736(21)01698-6
- STROKE STOP 10.1016/S0140-6736(21)01637-8
III. LAAC with AF ablation
Mandrola Previews the OPTION Trial, the Most Worrisome Study at AHA 2024
https://www.medscape.com/viewarticle/mandrola-previews-option-trial-most-worrisome-study-aha-2024-2024a1000kmz
- The OPTION Trial Rationale https://doi.org/10.1016/j.ahj.2022.05.003
IV. Blood Pressure Targets
- BPROAD https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13411
- ACCORD - https://www.nejm.org/doi/full/10.1056/NEJMoa1001286
V. GLP1a for HFpEF
- SUMMIT at Clinicaltrials.gov https://clinicaltrials.gov/study/NCT04847557
VI. VT Ablation
- VANISH2 Rationale https://doi.org/10.1016/j.ahj.2024.04.009
- VANISH 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
VII. Spironolactone Results of CLEAR-SYNERGY
Nov 08, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001865
'No Hint of Benefit' in Large Colchicine Trial
https://www.medscape.com/viewarticle/no-hint-benefit-large-colchicine-trial-2024a1000ko4
- CLEAR SYNERGY Rationale https://pubmed.ncbi.nlm.nih.gov/38936755/
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
